Mutlib Abdul, Jiang Ping, Atherton Jim, Obert Leslie, Kostrubsky Seva, Madore Steven, Nelson Sidney
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
Chem Res Toxicol. 2006 Oct;19(10):1270-83. doi: 10.1021/tx060093j.
The inability to predict if a metabolically bioactivated compound will cause toxicity in later stages of drug development or post-marketing is of serious concern. One approach for improving the predictive success of compound toxicity has been to compare the gene expression profile in preclinical models dosed with novel compounds to a gene expression database generated from compounds with known toxicity. While this guilt-by-association approach can be useful, it is often difficult to elucidate gene expression changes that may be related to the generation of reactive metabolites. In an effort to address this issue, we compared the gene expression profiles obtained from animals treated with a soft-electrophile-producing hepatotoxic compound against corresponding deuterium labeled analogues resistant to metabolic processing. Our aim was to identify a subset of potential biomarker genes for hepatotoxicity caused by soft-electrophile-producing compounds. The current study utilized a known hepatotoxic compound N-methylformamide (NMF) and its two analogues labeled with deuterium at different positions to block metabolic oxidation at the formyl (d(1)) and methyl (d(3)) moieties. Groups of mice were dosed with each compound, and their livers were harvested at different time intervals. RNA was prepared and analyzed on Affymetrix GeneChip arrays. RNA transcripts showing statistically significant changes were identified, and selected changes were confirmed using TaqMan RT-PCR. Serum clinical chemistry and histopathologic evaluations were performed on selected samples as well. The data set generated from the different groups of animals enabled us to determine which gene expression changes were attributed to the bioactivating pathway. We were able to selectively modulate the metabolism of NMF by labeling various positions of the molecule with a stable isotope, allowing us to monitor gene changes specifically due to a particular metabolic pathway. Two groups of genes were identified, which were associated with the metabolism of a certain part of the NMF molecule. The metabolic pathway leading to the production of reactive methyl isocyanate resulted in distinct expression patterns that correlated with histopathologic findings. There was a clear correlation between the expression of certain genes involved in the cell cycle/apoptosis and inflammatory pathways and the presence of reactive metabolite. These genes may serve as potential genomic biomarkers of hepatotoxicity induced by soft-electrophile-producing compounds. However, the robustness of these potential genomic biomarkers will need to be validated using other hepatotoxicants (both soft- and hard-electrophile-producing agents) and compounds known to cause idiosyncratic liver toxicity before being adopted into the drug discovery screening process.
在药物研发后期或上市后,无法预测代谢生物活化的化合物是否会导致毒性,这是一个严重令人担忧的问题。提高化合物毒性预测成功率的一种方法是,将用新型化合物给药的临床前模型中的基因表达谱,与由已知毒性化合物生成的基因表达数据库进行比较。虽然这种基于关联的方法可能有用,但通常很难阐明可能与活性代谢物生成相关的基因表达变化。为了解决这个问题,我们比较了用产生软亲电试剂的肝毒性化合物处理的动物,与相应的抗代谢处理的氘标记类似物所获得的基因表达谱。我们的目的是确定由产生软亲电试剂的化合物引起的肝毒性的潜在生物标志物基因子集。当前的研究使用了一种已知的肝毒性化合物N-甲基甲酰胺(NMF)及其在不同位置标记有氘的两种类似物,以阻断甲酰基(d(1))和甲基(d(3))部分的代谢氧化。给几组小鼠分别用每种化合物给药,并在不同时间间隔采集它们的肝脏。制备RNA并在Affymetrix基因芯片阵列上进行分析。鉴定出显示出统计学显著变化的RNA转录本,并使用TaqMan RT-PCR确认选定的变化。还对选定的样本进行了血清临床化学和组织病理学评估。从不同组动物生成的数据集使我们能够确定哪些基因表达变化归因于生物活化途径。我们能够通过用稳定同位素标记分子的不同位置来选择性地调节NMF的代谢,从而使我们能够监测特定代谢途径导致的基因变化。鉴定出两组基因,它们与NMF分子某一部分的代谢有关。导致活性异氰酸甲酯产生的代谢途径导致了与组织病理学发现相关的独特表达模式。参与细胞周期/凋亡和炎症途径的某些基因的表达与活性代谢物的存在之间存在明显的相关性。这些基因可能作为由产生软亲电试剂的化合物诱导的肝毒性的潜在基因组生物标志物。然而,在被纳入药物发现筛选过程之前,这些潜在基因组生物标志物的稳健性需要使用其他肝毒性物质(包括产生软亲电试剂和硬亲电试剂的物质)以及已知会引起特异质性肝毒性的化合物进行验证。